Drugs Made In America Acquisition Corp
DMAAR0.189USD
0.000
Close 12/18, 16:00（ET）Quotes delayed by 15 min
0.00Market Cap
--P/E TTM
More Details of Drugs Made In America Acquisition Corp Company
Drugs Made In America Acquisition Corp. is a blank check company. The Company is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combination with one or more businesses. The Company intends to focus its search for businesses in the pharmaceutical industry. The Company has neither engaged in any operations nor generated any revenues.
Drugs Made In America Acquisition Corp Info
Ticker SymbolDMAAR
Company nameDrugs Made In America Acquisition Corp
IPO dateJan 28, 2025
CEOStockwell (Lynn)
Number of employees- -
Security typeRight
Fiscal year-end- -
Address1 East Broward Boulevard
CityFT LAUDERDALE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code33301
Phone19548703099
Website
Ticker SymbolDMAAR
IPO dateJan 28, 2025
CEOStockwell (Lynn)
Company Executives of Drugs Made In America Acquisition Corp
Name
Name/Position
Position
Shareholding
Change
Mr. Saleem Elmasri, CPA
Mr. Saleem Elmasri, CPA
Chief Financial Officer, Principal Financial and Accounting Officer
Chief Financial Officer, Principal Financial and Accounting Officer
--
--
Dr. Catherine Do
Dr. Catherine Do
Independent Director Nominee
Independent Director Nominee
--
--
Dr. G. Sridhar Prasad
Dr. G. Sridhar Prasad
Independent Director Nominee
Independent Director Nominee
--
--
Mr. Myron W. Shulgan
Mr. Myron W. Shulgan
Independent Director Nominee
Independent Director Nominee
--
--
Ms. Lynn Stockwell
Ms. Lynn Stockwell
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Saleem Elmasri, CPA
Mr. Saleem Elmasri, CPA
Chief Financial Officer, Principal Financial and Accounting Officer
Chief Financial Officer, Principal Financial and Accounting Officer
--
--
Dr. Catherine Do
Dr. Catherine Do
Independent Director Nominee
Independent Director Nominee
--
--
Dr. G. Sridhar Prasad
Dr. G. Sridhar Prasad
Independent Director Nominee
Independent Director Nominee
--
--
Mr. Myron W. Shulgan
Mr. Myron W. Shulgan
Independent Director Nominee
Independent Director Nominee
--
--
Ms. Lynn Stockwell
Ms. Lynn Stockwell
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Other
100.00%
Shareholders
Shareholders
Proportion
Other
100.00%
Shareholder Types
Shareholders
Proportion
Other
100.00%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
40
17.99M
0.00%
-8.45K
2025Q3
40
18.00M
0.00%
-473.40K
2025Q2
29
18.49M
0.00%
+4.36M
2025Q1
20
14.06M
0.00%
+14.06M
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
TD Securities, Inc.
1.95M
0%
+1.95M
--
Jun 30, 2025
Harraden Circle Investments, LLC
1.50M
0%
--
--
Jun 30, 2025
Boothbay Fund Management, LLC
570.00K
0%
+570.00K
--
Jun 30, 2025
Mangrove Partners
850.00K
0%
--
--
Jun 30, 2025
ATW Spac Management LLC
570.00K
0%
--
--
Jun 30, 2025
Westchester Capital Management, LLC
500.00K
0%
+500.00K
--
Jun 30, 2025
Polar Asset Management Partners Inc.
1.90M
0%
--
--
Jun 30, 2025
Glazer Capital, LLC
1.30M
0%
--
--
Jun 30, 2025
Clear Street LLC
672.09K
0%
+121.91K
+22.16%
Jun 30, 2025
LMR Partners LLP
500.00K
0%
--
--
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
CrossingBridge Pre-Merger SPAC ETF
0%
CrossingBridge Pre-Merger SPAC ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Drugs Made In America Acquisition Corp?
The top five shareholders of Drugs Made In America Acquisition Corp are:
TD Securities, Inc. holds 1.95M shares, accounting for 0.00% of the total shares.
Harraden Circle Investments, LLC holds 1.50M shares, accounting for 0.00% of the total shares.
Boothbay Fund Management, LLC holds 570.00K shares, accounting for 0.00% of the total shares.
Mangrove Partners holds 850.00K shares, accounting for 0.00% of the total shares.
ATW Spac Management LLC holds 570.00K shares, accounting for 0.00% of the total shares.
TD Securities, Inc. holds 1.95M shares, accounting for 0.00% of the total shares.
Harraden Circle Investments, LLC holds 1.50M shares, accounting for 0.00% of the total shares.
Boothbay Fund Management, LLC holds 570.00K shares, accounting for 0.00% of the total shares.
Mangrove Partners holds 850.00K shares, accounting for 0.00% of the total shares.
ATW Spac Management LLC holds 570.00K shares, accounting for 0.00% of the total shares.
What are the top three shareholder types of Drugs Made In America Acquisition Corp?
The top three shareholder types of Drugs Made In America Acquisition Corp are:
Other
Other
How many institutions hold shares of Drugs Made In America Acquisition Corp (DMAAR)?
As of 2025Q4, 40 institutions hold shares of Drugs Made In America Acquisition Corp, with a combined market value of approximately 17.99M, accounting for --% of the total shares. Compared to 2025Q3, institutional shareholding has increased by --.
What is the biggest source of revenue for Drugs Made In America Acquisition Corp?
In --, the -- business generated the highest revenue for Drugs Made In America Acquisition Corp, amounting to -- and accounting for --% of total revenue.
